Publication: Diagnostic Yield and Safety of Bronchoscopist-directed Moderate Sedation with a Bolus Dose Administration of Propofol during Endobronchial Ultrasound Bronchoscopy
Issued Date
2018-07-01
Resource Type
ISSN
19488270
19446586
19446586
Other identifier(s)
2-s2.0-85041564869
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Bronchology and Interventional Pulmonology. Vol.25, No.3 (2018), 181-188
Suggested Citation
Danai Khemasuwan, Krittika Teerapuncharoen, David C. Griffin Diagnostic Yield and Safety of Bronchoscopist-directed Moderate Sedation with a Bolus Dose Administration of Propofol during Endobronchial Ultrasound Bronchoscopy. Journal of Bronchology and Interventional Pulmonology. Vol.25, No.3 (2018), 181-188. doi:10.1097/LBR.0000000000000462 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46561
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Diagnostic Yield and Safety of Bronchoscopist-directed Moderate Sedation with a Bolus Dose Administration of Propofol during Endobronchial Ultrasound Bronchoscopy
Abstract
© 2018 Wolters Kluwer Health, Inc. All rights reserved. Background: The propofol use for moderate sedation (MS) during endobronchial ultrasound (EBUS) bronchoscopy is primarily restricted for use by an anesthesiologist because of safety concerns. The goals of this study were to demonstrate the safety and the diagnostic yield of the use of propofol by bronchoscopists and trained endoscopy nurses during EBUS bronchoscopy without intubation. Methods: We tested a bolus propofol administration protocol targeting MS for EBUS bronchoscopy. A fixed initial dose of 40 mg of propofol along with a fixed 50 mcg fentanyl dose were administered. Sedation assessment was performed every 2 minutes, and repeated bolus doses of propofol were given to maintain MS under the direction of the bronchoscopist. Results: A total of 122 subjects underwent EBUS bronchoscopy with a goal of MS from August 2015 to April 2017. In total, 110 subjects who underwent convex EBUS bronchoscopy under MS with propofol were included in the analysis. Median procedure duration was 57 minutes (range, 15 to 97 min). Deep sedation and agitation-related delay were occurred in 14 and 21 subjects, respectively. Hemodynamic instability and hypoxemia occurred in 23 subjects. However, there was no need for vasopressors or artificial airway placement. Median of total propofol dose per case was 560 mg. Diagnostic yield for malignancy and granuloma was 68%, and a median of 4 lymph node stations were sampled per subject. All specimens with adenocarcinoma were sufficient for genetic marker analysis. There were no major sedation-related complications. Conclusion: A bolus administration of propofol during EBUS bronchoscopy provided excellent adequacy of sedation and well tolerance safety profile.